Valeant has sold its controversial female libido drug to former shareholders in Sprout, the company that first developed it before a $1 billion buyout two years ago.
Disc Medicine has charted a route to market for bitopertin, its drug candidate for rare disease erythropoietic protoporphyria (EPP), after meeting with the FDA.
